| General Information | |
|---|---|
| ZINC ID | ZINC000040913353 |
| Molecular Weight (Da) | 360 |
| SMILES | CCCCC/C=CC/C=CC/C=CC/C=CCCCC(=O)N[C@@H]1C[C@@H]1O |
| Molecular Formula | C23N1O2 |
| Action | Agonist |
| Physicochemical Details | |
|---|---|
| Molar Refractivity | 115.202 |
| HBA | 2 |
| HBD | 2 |
| Rotatable Bonds | 15 |
| Heavy Atoms | 26 |
| LogP | 5.417 |
| Activity (Ki) in nM | 151.356 |
| Polar Surface Area (PSA) | 49.33 |
| Pharmacokinetic Properties (AdmetSAR) | |
|---|---|
| Human intestinal absorption | + |
| Caco-2 | - |
| Blood brain barrier | + |
| P-glycoprotein inhibitior | - |
| P-glycoprotein substrate | - |
| Cyp3a4 substrate | + |
| Cyp2c9 substrate | + |
| Cyp2d6 substrate | - |
| Cyp3a4 inhibition | - |
| Cyp2c9 inhibition | - |
| Cyp2c19 inhibition | - |
| Cyp2d6 inhibition | - |
| Cyp1a2 inhibition | - |
| Acute oral toxicity | - |
| Carcinogenicity (binary) | - |
| Ames mutagenesis | - |
| Human ether-a-go-go-related gene inhibition | + |
| Biodegradation | - |
| Glucocorticoid receptor binding | + |
| Thyroid receptor binding | + |
| Androgen receptor binding | - |
| Plasma protein binding | 1.009 |
| Pharmacokinetic Properties (SwissADME) | |
|---|---|
| Number of aromatic heavy atoms | 0 |
| Fraction csp3 | 0.61 |
| Ilogp | 3.67 |
| Xlogp3 | 6.69 |
| Wlogp | 5.38 |
| Mlogp | 5.46 |
| Silicos-it log p | 6.74 |
| Consensus log p | 5.83 |
| Esol log s | -6.62 |
| Esol solubility (mg/ml) | 0.000106 |
| Esol solubility (mol/l) | 0.00000024 |
| Esol class | Poorly sol |
| Ali log s | -7.3 |
| Ali solubility (mg/ml) | 0.0000221 |
| Ali solubility (mol/l) | 5.03E-08 |
| Ali class | Poorly sol |
| Silicos-it logsw | -9.66 |
| Silicos-it solubility (mg/ml) | 9.54E-08 |
| Silicos-it solubility (mol/l) | 2.17E-10 |
| Silicos-it class | Poorly soluble |
| Pgp substrate | |
| Log kp (cm/s) | -4.23 |
| Lipinski number of violations | 1 |
| Ghose number of violations | 1 |
| Veber number of violations | 0 |
| Egan number of violations | 1 |
| Muegge number of violations | 1 |
| Bioavailability score | 0.55 |
| Pains number of alerts | 0 |
| Brenk number of alerts | 0 |
| Leadlikeness number of violations | 3 |
| Synthetic accessibility | 3.56 |
| Pharmacokinetic Properties (ADMETLab) | |
|---|---|
| Logs | -2.957 |
| Logd | 2.814 |
| Logp | 2.091 |
| F (20%) | 1 |
| F (30%) | 1 |
| Mdck | 8.59E-05 |
| Ppb | 0.9836 |
| Vdss | 1.124 |
| Fu | 0.0144 |
| Cyp1a2-inh | 0.147 |
| Cyp1a2-sub | 0.879 |
| Cyp2c19-inh | 0.466 |
| Cyp2c19-sub | 0.366 |
| Cl | 3.676 |
| T12 | 0.94 |
| H-ht | 0.215 |
| Dili | 0.023 |
| Roa | 0.003 |
| Fdamdd | 0.205 |
| Skinsen | 0.967 |
| Ec | 0.004 |
| Ei | 0.045 |
| Respiratory | 0.888 |
| Bcf | 1.18 |
| Igc50 | 4.851 |
| Lc50 | 2.672 |
| Lc50dm | 4.053 |
| Nr-ar | 0.006 |
| Nr-ar-lbd | 0.005 |
| Nr-ahr | 0.002 |
| Nr-aromatase | 0.054 |
| Nr-er | 0.102 |
| Nr-er-lbd | 0.009 |
| Nr-ppar-gamma | 0.955 |
| Sr-are | 0.732 |
| Sr-atad5 | 0.005 |
| Sr-hse | 0.915 |
| Sr-mmp | 0.335 |
| Sr-p53 | 0.453 |
| Vol | 413.203 |
| Dense | 0.87 |
| Flex | 2 |
| Nstereo | 2 |
| Nongenotoxic carcinogenicity | 0 |
| Ld50 oral | 0 |
| Genotoxic carcinogenicity mutagenicity | 0 |
| Surechembl | 0 |
| Nonbiodegradable | 0 |
| Skin sensitization | 0 |
| Acute aquatic toxicity | 0 |
| Toxicophores | 1 |
| Qed | 0.304 |
| Synth | 3.638 |
| Fsp3 | 0.609 |
| Mce-18 | 12.973 |
| Natural product-likeness | 0.697 |
| Alarm nmr | 0 |
| Bms | 0 |
| Chelating | 0 |
| Pfizer | 0 |
| Gsk | Accepted |
| Goldentriangle | Accepted |